Visual Atlas · Single-paper deep dive
Dölen 2023 — critical period reopening
A single 2023 Nature paper proposed a unifying mechanism for psychedelics: they reopen a childhood-like learning window, and how long the window stays open tracks how long the drug's effects last.
90-second quick read · deeper research available
Need the deeper research library?
This is the 90-second cliff-note read on imicrodosing.net. For cited research context, terminology, and broader education, use the full .org research library.
In brief
Critical periods are developmental windows when the brain learns certain things easily — language, vision, social bonding — and which normally close with maturity. Nardou, Dölen and colleagues (Nature 2023, 618:790–798) demonstrated in mice that psychedelics reopen the social reward learning critical period, and that this is a shared property across the drug class.
The striking finding: the duration of the reopened window is proportional to the duration of the drug's acute subjective effects in humans. Ketamine reopens it briefly, then MDMA, psilocybin and LSD progressively longer, with ibogaine longest. The work is a single, elegant animal study — a candidate unifying mechanism, not yet a human-confirmed one.
Visual walkthrough
Swipe or tap the arrows to move through 9 slides
What the paper found, and what it does not show yet
What a critical period is
A developmental window when specific learning happens easily — language, vision, social bonding — and which normally closes at maturity. Missing the window has lasting consequences.
The core result
In mice, psychedelics reopened the social reward learning critical period in adulthood. Reopening was shown as a property shared across the drug class, not unique to one compound.
The duration relationship
The length of the reopened window was proportional to each drug's acute subjective effect duration in humans — ketamine briefest, ibogaine longest, with MDMA, psilocybin and LSD in between.
The molecular parallel
Reopening coincided with restored oxytocin-mediated long-term depression in the nucleus accumbens and reorganisation of the extracellular matrix — a candidate shared downstream mechanism.
Why it is a big idea
It offers a single framework for why chemically different psychedelics share therapeutic and phenomenological features, and why duration of action might matter clinically.
The honest limit
This is one animal study. It is influential and well-designed, but human confirmation of the critical-period framework does not yet exist.
What the data shows — and how strong it is
Verdict
The mouse study offers a testable hypothesis about learning windows. Human timing, treatment use, and protocol design remain unconfirmed.
Common questions
Answered directly
Q · 01
What did the Dölen 2023 critical period study find?
Nardou, Dölen and colleagues (Nature 2023) demonstrated in mice that psychedelics reopen the social reward learning critical period, an effect shared across the drug class. Critically, the duration of the reopened window was proportional to each drug's acute subjective effect duration in humans.
Q · 02
Why are critical periods important for psychedelic therapy?
Critical periods are windows of heightened brain plasticity that normally close with maturity. If psychedelics reopen such a window, it offers a single framework for why different psychedelics share therapeutic effects, and why a drug's duration of action might determine how long the brain stays especially open to change.
Q · 03
Has the critical period theory been confirmed in humans?
No. The 2023 work is a single, well-designed animal study. The duration-of-effect correlation with human subjective reports is suggestive, but the framework has not been directly confirmed in people. Treat it as a leading hypothesis, not settled fact.
Product-format context
For product-format context, see the iMicrodosing.com products and client support.
View products & support →